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INCORPORATING OF HERD IMMUNITY INTO
PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL
CONJUGATE VACCINE PNC-7
Claes C1, Reinert RR2, Schulenburg JM1
1University of Hanover, Hannover, Germany; 2Institute for Medical
Microbiology, Aachen, Germany
OBJECTIVE: A general vaccination of newborns with PnC-7
reduces pneumococcal diseases and also the rate of pneumococ-
cal diseases in unvaccinated adults (herd immunity). Usually
cohort of patients followed subsequent cycles in a Markov
model. In this study, age and class were computed cross sec-
tionally. The objective of this study was to evaluate the annual
health outcomes and cost-effectiveness of a general vaccination
with PnC-7 in a hypothetical steady state German cohort across
all age groups with base year 2003 focusing health care payers’
perspective. METHODS: The efﬁcacies of PnC-7 and herd
immunity were adjusted to serotype distribution according to
two German panels. The model included incidences of pneumo-
coccal diseases, fatality rates, rate of long-term sequelae, age spe-
ciﬁc German population structure, 3 + 1 application of PnC-7,
and health care expenditures for treatment of pneumococcal dis-
eases. Critical key data were varied in a sensitivity analysis.
RESULTS: A vaccination rate PnC-7 of 68% is able to avoid
4256 invasive pneumococcal diseases, 57,727 pneumococcal
pneumonias, 274,332 cases of otitis media, 99 longterm seque-
laes and 2257 deaths resulting in 34,237 life years gained in
Germany every year. From health care payer’s view the cost
savings outweighed the vaccination administration with factor
1.23 and costs of a life-year-saved are 887€. The one-way sensi-
tivity analysis showed the estimations were sensitive to reduction
in incidence of otitis media and health care costs, but the vacci-
nation with PnC-7 remained cost saving. On the other hand, the
incorporation of an ageing German population, 2 + 1 applica-
tion of PnC-7, herd immunity without serotype adjustments or
non-discounting of life year gained resulted in conservative cost-
effectiveness estimations. CONCLUSIONS: From the German
health care payer view, a general vaccination with conjugate
vaccine PnC-7 is cost saving.
PIH2
THE COST-EFFECTIVENESS OF EXPANDING NEWBORN
SCREENING FOR INHERITED METABOLIC DISORDERS USING
TANDEM MASS SPECTROMETRY
Cipriano LE, Rupar CA, Zaric GS
University of Western Ontario, London, ON, Canada
OBJECTIVES: Currently, newborns in Ontario, Canada, are
screened for phenylketonuria (PKU) using the Guthrie method.
Tandem mass spectrometry (MS/MS) can allow several other
metabolic diseases to be screened for at birth. We estimated the
costs, health beneﬁts, and cost-effectiveness of using MS/MS to
expand the newborn screening program in Ontario to include 20
additional metabolic diseases. METHODS: We constructed a
decision-analytic model to estimate the incremental costs and life
years of survival gained associated with screening by MS/MS
versus the status quo (either not screening or screening with a
different technology). Disease prevalence, test characteristics,
treatment effectiveness, disease progression rates, and mortality
were estimated from secondary sources and expert opinion.
Costs were estimated primarily from the London Health Sciences
Center Case Costing Initiative, the Ontario Health Insurance
Plan Schedule of Beneﬁts, and the Ontario Drug Beneﬁts Plan
formulary. Costs and health beneﬁts were estimated for a cohort
of babies born in Ontario in one year. RESULTS: Using MS/MS
to screen for PKU has an incremental cost of $2,800,000 per life
year (LY) gained. When each additional disease was evaluated
independently, the cost of screening with MS/MS ranged from
cost-saving to $158,000/LY gained. Using MS/MS to screen for
PKU and 16 additional diseases costs $17,100/LY gained. CON-
CLUSIONS: Newborn screening reduces morbidity, mortality,
and the social burden of irreversible effects of disease on the pop-
ulation. The severity and onset of disease symptoms can be pre-
vented through early diagnosis and treatment. Our analysis
suggests that screening for PKU and 16 additional diseases has
an incremental cost effectiveness ratio below $50,000/LY gained.
However, it is not cost effective to screen for all diseases that can
be tested for using MS/MS.
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DIRECT COST OF TREATMENT FOR AUTISM SPECTRUM
DISORDER IN CALIFORNIA MEDICAID
Flanders S1, Engelhart L2
1Janssen Medical Affairs, Grayslake, IL, USA; 2Janssen Medical Affairs,
Titusville, NJ, USA
OBJECTIVE: To compare direct costs of treatment of children
(ages 3–17) with a diagnosis of an autism spectrum disorder
(autism) to a group of children having either a diagnosis of dia-
betes or asthma. METHODS: This was a retrospective, claims-
based study of children enrolled in the California Medicaid
(Medi-Cal) program from 1996–2002. Direct treatment costs
were based on utilization of inpatient, outpatient, pharmacy, and
ancillary services for all Medi-Cal eligible patients, starting 
six-months prior to a diagnosis of autism, diabetes, or asthma
(index date) to 12-months following a diagnosis. Medical and
prescription claims were categorized by psychiatric and non-
psychiatric services. Health care costs for autistic children were
then compared to costs from the randomly selected, gender
matched, cohorts of children with diabetes or asthma. Descrip-
tive statistics on demographics and non-parametric statistics on
costs (Kruskal-Wallis) were performed. RESULTS: The average
age of children with autism (n = 731) was 8.6 ± 4.0 years, com-
pared with diabetes (n = 731) 12.1 ± 4.3 years, and asthma (n =
731) 6.3 ± 3.0 years. A total of 75.4% of subjects were male.
Majority (37.1%) of the autism sample was White, while major-
ity of the asthma and diabetes children were Hispanic (44.1%
and 40.0%, respectively). Total median health care costs were
signiﬁcantly different among disease groups. Children with
autism had higher annual costs (pre-diagnosis: $363; post:
$1199) than children with diabetes (pre: $171; post: $649) or
asthma (pre: $147; post: $424) (all P < 0.0001). Psychiatric and
non-psychiatric cost categories were statistically signiﬁcant.
Additionally, the period prevalence for autism in this population
increased 114% over the study period, compared to a 42%
decrease in asthma and a 3% decrease in diabetes. CONCLU-
SIONS: This study estimates that autistic children incur greater
health care costs than children with diabetes or asthma. These
ﬁndings reﬂect the signiﬁcant cost of illness for autism 
relative to other chronic pediatric conditions in this Medi-Cal
population.
PIH4
THE QUALITY OF COMMUNITY PEDIATRICIAN’S
PRESCRIPTIONS
Triki N, Cohen R, Raz M
Maccabi Healthcare Services, Rishon Le Zion, Israel
There are several reasons why prescriptions for children’s med-
ications may have more mistakes than those for adults’ medica-
tions: dosage is adjusted to weight rather than being constant,
